US-based infusion centre operator IVX Health received $22.5m on Monday in a funding round co-led by McKesson Ventures, the investment arm of medical product distributor McKesson.
Venture capital firm Health Velocity Capital co-led the round, which also featured fellow VC firms Nueterra Capital and CrimsoNox Capital.
IVX Health operates centres that provide infusion and injection therapies for patients suffering with chronic conditions such as rheumatoid arthritis, Crohn’s disease and multiple sclerosis.
The company’s centres are open on evenings and weekends and offer private suites to each patient. It announced the new funding alongside its rebranding from Infusion Express.
IVX has a presence in Kansas City, Philadelphia, Chicago and San Francisco, and the cash will support the opening of new locations in cities such as Nashville, Harrisburg and Columbus.
McKesson Ventures led IVX’s $13.5m series B round in late 2017, investing alongside Health Velocity Capital. Nueterra Capital contributed to the latest round as an existing backer but has not revealed when it made its initial investment.
Dave Schulte, managing director of McKesson Ventures, said: “McKesson Ventures continues to support IVX Health’s vision to be the nation’s preferred destination for pharmaceutical care for patients with complex chronic conditions.
“We are excited to play a strategic role in IVX Health’s rapid growth as they pioneer a better care model that truly puts patients first.”